Consensus Pacific Biosciences of California, Inc.

Stocks

PACB

US69404D1081

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 00:00:00 26/08/2026 +04			5-day change	1st Jan Change
1.520 ^USD	+18.75%		+33.33%	-18.72%

08-06	Pacific Biosciences of California, Inc., Q2 2026 Earnings Call, Aug 05, 2026
08-06	Pacific Biosciences Announces Restructuring Plan, Cutting 8% of Workforce to Drive Up to $40 Million in Annual Savings by 2027	CI

Evolution of the Average Target: Pacific Biosciences of California, Inc.

Evolution of the Target Price: Pacific Biosciences of California, Inc.

Changes in Analyst Recommendations: Pacific Biosciences of California, Inc.

39.wWzes8L-5KyCuQBhw534Mqkp-qpYJhy3BgrQS5V-jBE.sRrm_LSvnNW74HBMifetZNtRw58OfizgQ1OpPMQa9GSwW-fEkrWKwbL4OA~c9b0fe75ef669549c36dc99f446db7e2

Analysts' recommendations: Pacific Biosciences of California, Inc.

08/08/25	PacBio reports smaller-than-expected loss in Q2	RE
14/02/25	UBS Adjusts Price Target on Pacific Biosciences of California to $1.50 From $2, Keeps Neutral Rating	MT
11/11/24	UBS Downgrades Pacific Biosciences of California to Neutral From Buy, Cuts Price Target to $2 From $12	MT
03/06/24	Jefferies & Co Initiates Coverage on Pacific Biosciences of California With Buy Rating, $4 Price Target	MT
15/05/24	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	MT
13/05/24	Piper Sandler Adjusts Price Target on Pacific Biosciences of California to $2 From $6.50, Maintains Neutral Rating	MT
22/04/24	JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight	MT
18/04/24	Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating	MT
18/04/24	Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7	MT
17/04/24	TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating	MT
10/04/24	Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating	MT
16/02/24	UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating	MT
02/01/24	UBS Lifts Price Target on Pacific Biosciences of California to $12.50 From $10, Keeps Buy Rating	MT
14/12/23	Guggenheim Initiates Pacific Biosciences of California With Neutral Rating	MT
17/11/23	UBS Upgrades Pacific Biosciences of California to Buy From Neutral, Cuts Price Target to $10 From $13	MT
06/11/23	Piper Sandler Trims Price Target on Pacific Biosciences of California to $8 From $9, Maintains Neutral Rating	MT
31/10/23	Cantor Fitzgerald Upgrades Pacific Biosciences of California to Overweight From Neutral, Cuts Price Target to $11 From $14	MT
24/10/23	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $10 From $13, Maintains Equal-Weight Rating	MT
29/09/23	Barclays Cuts Price Target on Pacific Biosciences of California $9 From $14, Maintains Equalweight Rating	MT
28/09/23	Bernstein Starts Pacific Biosciences of California With Outperform Rating, $11 Price Target	MT
04/08/23	UBS Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Neutral Rating	MT
03/08/23	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Equalweight Rating	MT
30/06/23	Goldman Sachs Starts Pacific Biosciences of California at Buy With $17 Price Target	MT
05/06/23	Canaccord Genuity Adjusts Price Target on Pacific Biosciences of California to $17 From $14, Maintains Buy Rating	MT
10/05/23	Barclays Initiates Pacific Biosciences of California at Equalweight With $14 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PACIFIC BIOSCIENCES OF CALIFORNIA, INC.					+50.77%
	THERMO FISHER SCIENTIFIC, INC.					+0.52%
	DANAHER CORPORATION					+5.55%
	INTUITIVE SURGICAL, INC.					+28.55%
	BOSTON SCIENTIFIC CORPORATION					+25.73%
	SIEMENS HEALTHINEERS AG					+13.59%
	EDWARDS LIFESCIENCES CORPORATION					+11.11%
	AGILENT TECHNOLOGIES, INC.					+3.93%
	WATERS CORPORATION					+5.2%
	ILLUMINA, INC.					-11.6%
	Average					+13.33%
	Weighted average by Cap.					+9.71%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.520USD

Average target price

2.292USD

Spread / Average Target

+50.77%

High Price Target

3.000USD

Spread / Highest target

+97.37%

Low Price Target

1.250USD

Spread / Lowest Target

-17.76%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Jefferies & Co.
Morgan Stanley
Piper Sandler
JPMorgan Chase
Scotiabank
Goldman Sachs
TD Cowen
Guggenheim
Cantor Fitzgerald
Barclays
Bernstein
Canaccord Genuity
J.P. Morgan Chase